The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. RESULTS: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P<0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P<0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10%) in the elotuzumab group and were grade 1 or 2 in 29 patients. CONCLUSIONS: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number, NCT01239797.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike daratumumab, elotuzumab does not have single-agent activity but shows synergistic activity when combined with Rd (Table 8).84”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [84]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Elotuzumab targets SLAMF7; daratumumab and isatuximab target CD38 respectively.84–87”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [30]
In the citing paper
“Elotuzumab has been proposed to function at least partially through upregulation of IL-2 production by T cells and stimulation of natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC)68–70.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationCS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S. M., Draksharapu, A., Shum, B. P., Huseni, M. A., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 558
SLAM Family Receptors and SAP Adaptors in Immunity
Cannons, J. L., Tangye, S. G., & Schwartzberg, P. L. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101302 · Cited by 502
Tai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472
Self-citationVoskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 465
Dimopoulos, M. A., Chen, C. L., Spencer, A. G., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 366
Self-citationCollins, S. M., Bakan, C. E., Swartzel, G. D., Hofmeister, C. C., Efebera, Y. A., Kwon, H., Starling, G. C., Ciarlariello, D., Bhaskar, S., Briercheck, E. L., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1493-8 · Cited by 296
Richardson, P. G. G., Baz, R., Wang, M. L., Jakubowiak, A. J., Laubach, J. P., Harvey, R. D., Talpaz, M., Berg, D. T., Liu, G., Jiang, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548826 · Cited by 202
Self-citationPérez‐Quintero, L., Roncagalli, R., Guo, H., Latour, S., Davidson, D., & Veillette, A. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132038 · Cited by 93
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,000
Orphan drug approvals of 2015: Europe and the United States
Norman, P. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1167595 · Cited by 8
Iida, S., Wakabayashi, M., Tsukasaki, K., Miyamoto, K., Maruyama, D., Yamamoto, K., Takatsuka, Y., Kusumoto, S., Kuroda, J., Ando, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13550 · Cited by 9
Elotuzumab-induced interstitial lung disease: the first case report
Tanaka, T., Saito, Y., Kokuho, N., Tamura, H., Terasaki, Y., Seike, M., & Gemma, A. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy049 · Cited by 8
Hari, P., Lin, H. M., Zhu, Y., Berg, D. T., Richardson, P. G. G., & Moreau, P. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1474745 · Cited by 8
Self-citationToxicity management strategies for next-generation novel therapeutics in multiple myeloma
Steinbach, M. N., Julian, K. L., McClune, B. L., & Sborov, D. W. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221100659 · Cited by 8
Yue, Y., Cao, Y., Mao, X., Wang, F., Fan, P., Qian, L., Guo, S., Li, F., Guo, Y., Chen, T., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894279 · Cited by 8
Assidi, M. (2022) · Oncology Letters · doi:10.3892/ol.2022.13553 · Cited by 8
Moscvin, M., Evans, B., & Bianchi, G. (2023) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.110 · Cited by 8
Sun, L., Ren, J., Feng, X., Li, S., Wang, Y., Jiang, Y. Z., & Zheng, C. (2023) · Pharmacognosy Magazine · doi:10.1177/09731296231170926 · Cited by 8
Bruno, B., Auner, H. W., Gahrton, G., Garderet, L., Festuccia, M. B., Ladetto, M., Lemoli, R. M., Massaia, M., Morris, C., Palumbo, A. P., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1131278 · Cited by 8
Self-citationGarderet, L., Cook, G., Auner, H. W., Bruno, B., Lokhorst, H. M., Pérez‐Simón, J. A., Sahebi, F., Scheid, C., Morris, C., van Biezen, A., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1228926 · Cited by 8
Elotuzumab as a novel anti-myeloma immunotherapy
Radhakrishnan, S. V., Bhardwaj, N., Steinbach, M. N., Weidner, J., Luetkens, T., & Atanackovic, D. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1327487 · Cited by 8
Triplet therapies – the new standard of care for multiple myeloma: how to manage common toxicities
Paner, A., Okwuosa, T. M., Richardson, K. J., & Libby, E. N. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1538777 · Cited by 8
Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma
Nooka, A. K., & Lonial, S. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000354 · Cited by 8
Self-citationon behalf of the European Myeloma Network, Caballero‐Velázquez, T., Calderón‐Cabrera, C., López‐Corral, L., Puig, N., Márquez-Malaver, F. J., Pérez‐López, E., García-Calderón, C. B., Rosso-Fernández, C. M., Caballero, D. M., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0670-6 · Cited by 8
Self-citationThe safety of current and emerging therapies for multiple myeloma
Nadeem, O., & Anderson, K. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1733968 · Cited by 8
Self-citationSelinexor for the treatment of patients with previously treated multiple myeloma
Mo, C. C., Jagannath, S., Chari, A., Nooka, A. K., Lonial, S., Siegel, D. S. D., Biran, N., Gasparetto, C., Bahlis, N. J., & Richardson, P. G. G. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1923473 · Cited by 8
Self-citationMultiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00101-8 · Cited by 8
The Clinical Pharmacology of Elotuzumab
Passey, C., Sheng, J., Mora, J. R., Tendolkar, A. V., Robbins, M. D. H., Dodge, R. W., Roy, A., Bello, A., & Gupta, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0585-6 · Cited by 8
Pharmacokinetics and Pharmacodynamics of Immunotherapy
Lam, L. H., Lin, S., & Sun, J. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_2 · Cited by 8
Merz, A. M. A., Merz, M., Hillengaß, J., Holstein, S. A., & McCarthy, P. L. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1674142 · Cited by 8
Basic, E., Kappel, M., Misra, A., Sellner, L., Ratsch, B. A., & Ostwald, D. A. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01219-3 · Cited by 8
Zolnowski, D., Karp, S., Warncke, P., Zinn, J., Pannach, M., Herbst, R., Hänel, A., Morgner, A., Ibach, S., Fricke, S., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05993-y · Cited by 7
Current Treatment Strategies for Multiple Myeloma at First Relapse
Mavrothalassitis, E., Triantafyllakis, K., Malandrakis, P., Gavriatopoulou, M., Kleber, M., & Ntanasis‐Stathopoulos, I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051655 · Cited by 7
Current treatment options of T cell-associated immunotherapy in multiple myeloma
Liu, H., Pan, Y., Meng, S., Zhang, W., & Zhou, F. (2017) · Clinical and Experimental Medicine · doi:10.1007/s10238-017-0450-9 · Cited by 7
Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma
Neri, P. E., & Nijhof, I. S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104041 · Cited by 7
Lu, J., Hou, J., Liu, K., Parmar, S., de la Fuente, A., Andersson, B., Yan, C., Zhou, D., Tan, D. C. L., Ritchie, D., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1135434 · Cited by 7
Self-citationMonoclonal Antibodies for the Treatment of Myeloma
Lonial, S. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000172 · Cited by 7
Self-citationSchieferdecker, A., Oberle, A., Thiele, B., Hofmann, F., Göthel, M., Miethe, S., Hust, M., Braig, F., Voigt, M., von Pein, U., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676536 · Cited by 7
Terpos, E., Gobbi, M., Potamianou, A., Lahaye, M., Couturier, C., & Cavo, M. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12937 · Cited by 7
Dhakal, B., Narra, R. K., Giri, S., Szabó, A., Smunt, T. L., Ghose, S., Pathak, L. K., Aryal, M. R., Hamadani, M., Chhabra, S., et al. (2020) · Cancer · doi:10.1002/cncr.32831 · Cited by 7
Sessa, M., Cavazzini, F., Cavallari, M., Rigolin, G. M., & Cuneo, A. (2020) · Genes · doi:10.3390/genes11121453 · Cited by 8
Krzywdzińska, A., Puła, B., Czyż, A., Krzymieniewska, B., Kiernicka‐Parulska, J., Mierzwa, A., Szymczak, D., Milanowska, A., Kiraga, A., Kwiecień, I., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11101872 · Cited by 7
Richardson, K., Keam, S. P., Zhu, J. J., Meyran, D., D’Souza, C., Macdonald, S., Campbell, K. S., Robbins, M. D. H., Bezman, N., Todd, K. L., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.279930 · Cited by 7
Development of targeted therapies in IgG4-related disease
Nakayamada, S., & Tanaka, Y. (2022) · Modern Rheumatology · doi:10.1093/mr/roac096 · Cited by 7
Baz, R., Zonder, J. A., Gasparetto, C., Reu, F. J., & Strout, V. (2016) · Oncology and Therapy · doi:10.1007/s40487-016-0034-y · Cited by 7
Iida, S., Nagai, H., Kinoshita, G., Miyoshi, M., Robbins, M. D. H., Pandya, D., Bleickardt, E. W., & Chou, T. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2138-4 · Cited by 7
Self-citationBaertsch, M., Hundemer, M., Hillengaß, J., Goldschmidt, H., & Raab, M. S. (2017) · Hematological Oncology · doi:10.1002/hon.2473 · Cited by 7
Alternative metrics for assessing clinical benefit with immunotherapy in oncology
Chan, E., Quinn, C., Hirji, I., Hillengaß, J., Anderson, K. C., Oukessou, A., & Davis, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1343774 · Cited by 7
Self-citationD’Agostino, M., Gazzera, G., Cetani, G., Bringhen, S., Boccadoro, M., & Gay, F. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180514114806 · Cited by 7
Venken, K., Favreau, M., Gaublomme, D., Menu, E., Vanderkerken, K., & Elewaut, D. S. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.08.019 · Cited by 7
Limited treatment options in refractory multiple myeloma: promising therapeutic developments
Oriol, A., Abril, L., Ibarra, G., & Senín, A. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1708721 · Cited by 7
Outcomes of lenalidomide‐ or bortezomib‐based regimens in older patients with plasma cell myeloma
Barth, P. M., Giri, S., Reagan, J. L., & Olszewski, A. J. (2020) · American Journal of Hematology · doi:10.1002/ajh.25996 · Cited by 7
Old and new generation immunomodulatory drugs in multiple myeloma
Derudas, D., Capraro, F., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04125-7 · Cited by 7
Maouche, N., Kishore, B., Jenner, M. W., Boyd, K. D., Bhatti, Z., Bird, S. A., Chander, G., Robinson, R., Vallance, G. D., Offer, M., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1864355 · Cited by 7
Lapietra, G., Fazio, F., & Petrucci, M. T. (2022) · Biomolecules · doi:10.3390/biom12081146 · Cited by 8
Schmitt, M. W., Hückelhoven, A. G., Hundemer, M., Schmitt, A., Lipp, S., Emde, M., Salwender, H. J., Hänel, M., Weisel, K. C., Bertsch, U., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11215 · Cited by 7
The safety of daratumumab for the treatment of multiple myeloma
Cejalvo, M. J., Ribas, P., & de la Rubia, J. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1328053 · Cited by 7
Ziogas, D. C., Terpos, E., Gavriatopoulou, M., Migkou, M., Fotiou, D., Ρούσσου, Μ., Kanellias, N., Tatouli, I. P., Eleutherakis‐Papaiakovou, E., Panagiotidis, I., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1361031 · Cited by 7
Self-citationKobayashi, T., Miura, M., Abumiya, M., Akamine, Y., Ito, F., & Takahashi, N. (2019) · Medical Oncology · doi:10.1007/s12032-019-1280-2 · Cited by 7
Pleural plasmacytomas – the role of radiotherapy
Yeoh, K., Thitsar, S. M., Master, Z., Loh, Y., Chen, Y., Nagarajan, C., Tin, K., Cutter, D. J., & Mikhaeel, N. G. (2020) · British Journal of Haematology · doi:10.1111/bjh.16770 · Cited by 7
Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients
Premkumar, V. J., Bhutani, D., & Lentzsch, S. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.06.023 · Cited by 7
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma
Pantani, L., Brioli, A., Tacchetti, P., Zannetti, B. A., Mancuso, K., Rocchi, S., Martello, M., Rizzello, I., Terragna, C., Zamagni, E., et al. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1127754 · Cited by 7
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts
Delforge, M., Vlayen, S., & Kint, N. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1905513 · Cited by 6
Multiple Myeloma: Risk Factors, Pathogenesis and Relationship with Anti-myeloma Therapies
Nwabuko, O. C. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2022.00059 · Cited by 6
Davies, F. E., Leleu, X. P., Vogel, P., Dhanasiri, S., Nouveau, P. L., & Weisel, K. C. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.07.010 · Cited by 6
Lee, J. H., Choi, J., Min, C., Park, S., Jo, J., Lee, Y. J., Kim, J. S., Eom, H., Jung, J., Moon, J. H., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285534 · Cited by 6
Voorhees, P. M., Suman, V. J., Efebera, Y. A., Raje, N. S., Tuchman, S. A., Valdes, C. R., Laubach, J. P., Bova‐Solem, M., Carlisle, D., Usmani, S. Z., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013623 · Cited by 6
Self-citationApproaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?
Vijjhalwar, R., Kannan, A., Fuentes-Lacouture, M. C., & Ramasamy, K. (2025) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-025-02008-9 · Cited by 6
Efficacy and safety of elotuzumab for the treatment of multiple myeloma
Gavriatopoulou, M., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1279603 · Cited by 6
Self-citationCurrent and prospective antibody-based therapies in multiple myeloma
Bryer, E. J., DeStefano, C. B., & Kazandjian, D. G. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.11.002 · Cited by 6
Tauseef, A., Zafar, M., Silberstein, P. T., Nahas, J., Frederickson, T., Abodunrin, F., Abbas, A., Arshad, W., Lateef, N., Rangoonwala, H. I., et al. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1987_21 · Cited by 6
Shimazu, Y., Kanda, J., Kosugi, S., Ito, T., Kaneko, H., Imada, K., Shimura, Y., Fuchida, S., Fukushima, K., Tanaka, H., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-32426-6 · Cited by 6
Bhutani, M., Foureau, D., Robinson, M. M., Guo, F., Fesenkova, K., Atrash, S., Paul, B. A., Varga, C., Friend, R. N., Pineda‐Roman, M., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.03.016 · Cited by 6
Monoclonal Antibody Therapy in Multiple Myeloma: Where do we Stand and Where Are We Going?
Thanendrarajan, S., Davies, F. E., Morgan, G. J., Schinke, C., Mathur, P., Heuck, C. J., Zangari, M., Epstein, J., Yaccoby, S., Weinhold, N., et al. (2016) · Immunotherapy · doi:10.2217/imt.15.118 · Cited by 6
Practical Approaches to the Management of Dual Refractory Multiple Myeloma
Lee, H. C., Mark, T. M., & Shah, J. J. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0312-7 · Cited by 6
High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges
Muchtar, E., Magen, H., & Gertz, M. A. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1233540 · Cited by 6
Self-citationAdvances and practical use of monoclonal antibodies in multiple myeloma therapy
Lee, H. C., & Weber, D. M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.512 · Cited by 6
LeBlanc, T. W., Howson, A., Turell, W., Sheldon, P., Locke, S. C., Tuchman, S. A., Gasparetto, C., Kaura, S., Khan, Z., & Abernethy, A. P. (2016) · Current Oncology · doi:10.3747/co.23.3298 · Cited by 6
Assessment of Hazard Ratios in Oncology Clinical Trials Terminated Early for Superiority
Shimura, M., Nomura, S., Wakabayashi, M., Maruo, K., & Gosho, M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8633 · Cited by 6
Wu, Y., Wu, X., Liu, X., Zheng, X. Y., Deng, J., & Gong, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08588-9 · Cited by 6
Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide
Wang, H., Shi, H. W., Yan, W., He, X., & Liao, A. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s300328 · Cited by 6
Bergin, K., Yuen, F., Wallington-Beddoe, C. T., Kalff, A., Sirdesai, S., Reynolds, J., & Spencer, A. G. (2021) · British Journal of Haematology · doi:10.1111/bjh.17504 · Cited by 6
Self-citationComdühr, S., Dübbers, A., Tharun, L., Graßhoff, H., Stone, J. H., Pitann, S., Riemekasten, G., & Lamprecht, P. (2022) · Rheumatology · doi:10.1093/rheumatology/keac302 · Cited by 6
Mangiacavalli, S., Cartia, C. S., Galli, M., Pezzatti, S., Belotti, A., Fazio, F., Mina, R., Marcatti, M., Cafro, A. M., Zambello, R., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281342 · Cited by 6
Ojo, A. S., Araoye, M. O., Ali, A. S., & Sarma, R. (2023) · Journal of Cancer Survivorship · doi:10.1007/s11764-023-01332-1 · Cited by 6
Risk-Based Therapeutic Strategies
Corre, J., & Avet‐Loiseau, H. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000352 · Cited by 6
A review of epidemiology and management of multiple myeloma in a resource poor country
Akinbami, A., Dosunmu, A. O., & Uche, E. I. (2018) · Annals of Tropical Pathology · doi:10.4103/atp.atp_8_18 · Cited by 6
MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy
Kurihara, K., Iriyama, N., Miura, K., Uchino, Y., Takahashi, H., Nakagawa, M., Iizuka, K., Hamada, T., Koike, T., Hatta, Y., et al. (2019) · Medical Oncology · doi:10.1007/s12032-019-1298-5 · Cited by 6
Toxicities of novel therapies for hematologic malignancies
Simon, F., Borrega, J. G., & Bröckelmann, P. J. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1728249 · Cited by 6
Devarakonda, S. S., Cottini, F., Bumma, N., Khan, A., Sharma, N., Chaudhry, M., Benson, D., Rosko, A. E., & Efebera, Y. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113626 · Cited by 6
Elotuzumab in the Treatment of Relapsed and Refractory Multiple Myeloma
Grosicki, S., Bednarczyk, M., Barchnicka, A., & Grosicka, O. (2021) · Future Oncology · doi:10.2217/fon-2020-1088 · Cited by 6
Self-citationAntibody‐based immunotherapy for treatment of immunoglobulin light‐chain amyloidosis
Parrondo, R. D., Majeed, U., & Sher, T. (2020) · British Journal of Haematology · doi:10.1111/bjh.16697 · Cited by 6
Introduction to “Immunotherapies for Multiple Myeloma”
Offidani, M., & Petrucci, M. T. (2020) · Pharmaceuticals · doi:10.3390/ph13110396 · Cited by 6
Kegyes, D., Moisoiu, V., Constantinescu, C. S., Tănase, A., Ghiaur, G., Einsele, H., Tomuleasa, C., Lazarus, H. M., & Gale, R. P. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101254 · Cited by 5
Self-citationIncorporating mRNA therapeutics into biological treatments of hematologic malignancies
Hunia, J., Tomasik, J., Czerwik, N., Pezeshki, P. S., & Nowis, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680071 · Cited by 6
Pipe dream to pipeline: Journey of cancer vaccines and the road ahead
Onkar, S., Bozkus, C. C., Saxena, M., & Bhardwaj, N. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102575 · Cited by 5
Noori, M., Fayyaz, F., & Rezaei, N. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2169139 · Cited by 5
Barilà, G., Quaglia, F. M., Furlan, A., Pescosta, N., Bonalumi, A., Marcon, C., Pascarella, A., Tinelli, M., March, E. D., Liço, A., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05443-8 · Cited by 5
Cicala, G., Russo, G., Santoro, V., Franchina, T., Silvestris, N., Santarpía, M., Spina, E., & Barbieri, M. A. (2024) · Pharmaceuticals · doi:10.3390/ph17101266 · Cited by 5
Chromosome 1 Alterations in Multiple Myeloma: Considerations for Precision Therapy
McAuley, N., Cymer, I., McAvera, R. M., Hopkins, A. M., & Glavey, S. V. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14352 · Cited by 6
Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma
Richter, J. R., & Jagannath, S. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.09.003 · Cited by 5
The Role of Imaging and Systemic Treatments in Myeloma: A Primer for Radiologists
Marshall, C., Frantz, N., Kikano, E. G., Smith, D. A., Güler, E., Tirumani, S. H., & Ramaiya, N. H. (2020) · American Journal of Roentgenology · doi:10.2214/ajr.19.21725 · Cited by 5
Ide, T., Roy, A., Imai, Y., & Vezina, H. E. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1698 · Cited by 5
Biological research on the occurrence and development of multiple myeloma and its treatment
Wu, Y., Shi, X., Yao, X., & Du, X. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.850 · Cited by 5
Horigome, Y., Iino, M., Harazaki, Y., Kobayashi, T., Handa, H., Hiramatsu, Y., Kuroi, T., Tanimoto, K., Matsue, K., Abe, M., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05428-7 · Cited by 5
Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line
Hartley-Brown, M. A., & Zinkeng, A. (2023) · Hematology · doi:10.1182/hematology.2023000444 · Cited by 5
García‐Guiñón, A., Charry, P. A., Lorenzo, M.-J. J., Sarrà, J., Delgado, I., de la Torre, L. S., Santaliestra, M., García‐Pintos, M., Gonzalez, Y., Senín, A., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06240-1 · Cited by 5
Novel combination approaches for myeloma
Lonial, S., & Nooka, A. K. (2015) · Hematology · doi:10.1182/asheducation-2015.1.286 · Cited by 5
Self-citationSalvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
Thumallapally, N., Yu, H., Asti, D., Vennepureddy, A., & Terjanian, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s110189 · Cited by 5
Metadata
- Authors
- Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R. Z., Taniwaki, M., Röllig, C., Einsele, H., Wu, K. L., Singhal, A., San-Miguel, J., Matsumoto, M., Katz, J., Bleickardt, E., Poulart, V., Anderson, K. C., & Richardson, P.
- Affiliations
- Dalhousie University (CA)
- National and Kapodistrian University of Athens (GR)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Medical University of Silesia (PL)
- Centre Hospitalier Universitaire de Nantes (FR)
- Tel Aviv University (IL)
- University of Alberta (CA)
- Princess Margaret Cancer Centre (CA)
- Alfred Health (AU)
- Barts Health NHS Trust (GB)
- The University of Texas MD Anderson Cancer Center (US)
- Kyoto Prefectural University of Medicine (JP)
- Technische Universität Dresden (DE)
- Universitätsklinikum Würzburg (DE)
- Ziekenhuisnetwerk Antwerpen Stuivenberg (BE)
- AbbVie Biotherapeutics (United States) (US)
- National Hospital Organization (JP)
- Bristol-Myers Squibb (United States) (US)
- Dana-Farber Cancer Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-13
- Volume
- 373
- Issue
- 7
- Pages
- 621-631
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2201190784
- Semantic Scholar
- fb9d8d9019089b66fbe8ecd85963014c537e649e
- Cited by
- 1,322
- References
- 15
- Citations by year
- 2026: 29 · 2025: 60 · 2024: 63 · 2023: 87 · 2022: 95 · 2021: 147 · 2020: 174 · 2019: 132 · 2018: 154 · 2017: 187 · 2016: 160 · 2015: 33
- FWCI
- 139.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- AbbVie Biotherapeutics
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- elotuzumab, relapsed/refractory multiple myeloma, SLAMF7, lenalidomide, dexamethasone, progression-free survival, overall response rate, monoclonal antibodies, combination therapy, adverse events, lymphopenia, neutropenia, infusion reactions, interim analysis, overall survival
- MeSH terms
- Signaling Lymphocytic Activation Molecule Family, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Middle Aged, Multiple Myeloma, Receptors, Immunologic, Recurrence, Thalidomide, Disease-Free Survival, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
